Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting

Adverse Event ◽

Bowel Disease ◽

Dipeptidyl Peptidase ◽

Adverse Event Reporting ◽

Event Reporting ◽

Dipeptidyl Peptidase 4 ◽

Drug Adverse Event ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2013.04.031 ◽

2013 ◽

Vol 69 (3) ◽

pp. 393-398 ◽

Cited By ~ 16

Author(s):

Derrick J. Stobaugh ◽

Parakkal Deepak ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Food And Drug Administration ◽

Adverse Event Reporting ◽

Event Reporting ◽

Su1158 Risk of Leukemia With Pharmacotherapy Among Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System

Gastroenterology ◽

10.1016/s0016-5085(13)61525-5 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-414

Author(s):

Parakkal Deepak ◽

Derrick J. Stobaugh ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Food And Drug Administration ◽

Adverse Event Reporting ◽

Event Reporting ◽

Concomitant Antibiotic Usage Does Not Further Increase the Risk of Inflammatory Bowel Disease with Isotretinoin Treatment for Acne: A Review of the Food and Drug Administration Adverse Event Reporting System

The American Journal of Gastroenterology ◽

10.14309/00000434-201210001-01596 ◽

2012 ◽

Vol 107 ◽

pp. S645

Author(s):

Derrick Stobaugh ◽

Parakkal Deepak ◽

Eli Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Antibiotic Usage ◽

Event Reporting ◽

Disproportionate Lawyer Reporting of Inflammatory Bowel Disease Cases with Isotretinoin: A Review of the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS)

The American Journal of Gastroenterology ◽

10.14309/00000434-201210001-01583 ◽

2012 ◽

Vol 107 ◽

pp. S638-S639

Author(s):

Derrick Stobaugh ◽

Parakkal Deepak ◽

Muhammed Sherid ◽

Eli Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Food And Drug Administration ◽

Adverse Event Reporting ◽

Event Reporting ◽

Su1149 Drug Induced Lupus (DIL) With Adalimumab and Certolizumab in Infliximab Naïve Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System

Gastroenterology ◽

10.1016/s0016-5085(13)61516-4 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-411-S-412 ◽

Cited By ~ 1

Author(s):

Parakkal Deepak ◽

Derrick J. Stobaugh ◽

Brett D. Riederman ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Drug Induced ◽

Event Reporting ◽

Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting

Therapeutic Advances in Chronic Disease ◽

10.1177/2040622320904301 ◽

2020 ◽

Vol 11 ◽

pp. 204062232090430

Author(s):

Dandan Li ◽

Jocelyn Anne Silvester ◽

Matthew J. Crowley ◽

Jeff Y. Yang ◽

Anastasia-Stefania Alexopoulos ◽

...

Keyword(s):

Adverse Event ◽

Celiac Disease ◽

Dipeptidyl Peptidase ◽

Adverse Event Reporting ◽

Event Reporting ◽

Dipeptidyl Peptidase 4 ◽

Drug Adverse Event ◽

Dipeptidyl Peptidase 4 Inhibitors

Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-018-03763-5 ◽

2019 ◽

Vol 83 (3) ◽

pp. 599-601 ◽

Cited By ~ 3

Author(s):

Huaqiang Zhou ◽

Jiaqing Liu ◽

Yaxiong Zhang ◽

Li Zhang

Keyword(s):

Adverse Event ◽

Combination Treatment ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Event Reporting ◽

Su1160 Risk of Melanoma and Non-Melanoma Skin Cancers With Pharmacotherapy Among Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System

Gastroenterology ◽

10.1016/s0016-5085(13)61527-9 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-415 ◽

Cited By ~ 2

Author(s):

Derrick J. Stobaugh ◽

Parakkal Deepak ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Event Reporting ◽

Skin Cancers ◽

Inflammatory Bowel ◽

Melanoma Skin

Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System

European Journal of Clinical Pharmacology ◽

10.1007/s00228-012-1416-1 ◽

2012 ◽

Vol 69 (4) ◽

pp. 1041-1042

Author(s):

Derrick J. Stobaugh ◽

Parakkal Deepak ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Antibiotic Usage ◽

Event Reporting ◽

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults

Diabetes Care ◽

10.2337/dc19-0162 ◽

2019 ◽

Vol 42 (11) ◽

pp. 2065-2074

Author(s):

Tiansheng Wang ◽

Jeff Y. Yang ◽

John B. Buse ◽

Virginia Pate ◽

Huilin Tang ◽

...

Keyword(s):

Real World ◽

Bowel Disease ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Real World Evidence ◽

Dipeptidyl Peptidase 4 Inhibitors ◽